Colon Cancer Screening Strategies to improve prevention and early detection
Authored by
Luiz Ronaldo Alberti
Opinion
Colorectal carcinoma (CRC) is a common cause of death
and may be prevented by routine screening strategies in order to detect
precancerous lesions and early cancers [1].
However, colorectal screening is under used, and at least 40% of age-
eligible adults do not adhere to up-to-date screening guidelines. Three
strategies may increase compliance on colon cancer screening rates: to
convince the population and medical doctors about the importance of
undergoing a screening test; to achieve higher efficacy in standard
screening tests; to develop new more sensitive and efficacious screening
methods.
Physicians are increasingly aware of the importance
of screening to reduce mortality caused by CRC. Despite this fact, many
patients do not receive this needed recommendation. This recommendation
is of vital importance in order to convince patients to prevent CCR [2].
When screening tests are considered, the perfect
knowledge of each exam limits and periodicity is necessary to make the
CRC screening test more efficacious. Colonoscopy is an important method
and is largely used to evaluate the colon. As a major advantage, this
test frequently allows for the treatment of some affections immediately
upon diagnosis (e.g. polypectomy, dilatation, hemostasis), behaving as a
propedeutic and therapeutic method [3].
When properly executed by a well-trained
professional, under adequade bowel preparation, a colonoscopy can be
considered safe, precise, and easily tolerated by patients. American
Society for Gastrointestinal Endoscopy (ASGE) and the American College
of Gastroenterology (ACG) Task Force on Quality in Endoscopy defined
quality indicator in colonoscopy to improve the quality of the exam and
reduce complications, especially the number of missed [4].
These indicators were organized in three moments: before, during, and
after the procedure. Every endoscopist must understand and target each
item. Knowing the technique is not enough; it must also be
well-executed. The main value of a colonoscopy as a screening method
depends on the quality of the exam, as the findings (particularly
polyps) are definitive to determining the interval of future
colonoscopies. The most important quality indicators are: Quality of
bowel preparation, Ceccum intubation, Adenoma detection rate (ADR) in
asymptomatic average risk patients: must be over 25% in screened
populations and Withdrawal tim [4].
Ideally, all endoscopists should measure, register, and interpret their
own quality indicators in colonoscopy. Colonoscopy, to be cost-
effective as a CRC screening method, must be executed according to
quality indicator parameters [4].
The patient should be recommended to an adequate pst-
colonoscopy follow-up. Colonoscopy intervals are a key-points in CRC
screening. This interval is often a decision made by the physician who
requested the first exam. However, not all nonendoscopists know how to
correctly interpret the results of colonoscopy exams and hystological
findings to determine the best interval. In these situations, there is a
tendency to shorten intervals. Unnecessary and early request of
colonoscopy commits its cost-effectiveness, exposes patients to
unnecessary risks, and onerates the health care system.
The most recent recommendation regarding postpolypectomy surveillance was published in 2012 [5]
and adapted as a clinical decision tool from AGA in 2014. They
recommend follow-up based on endoscopic and hystological findings. To
follow the recommendations, a complete exam (up to the ceccum) must be
performed, with excellent quality of bowel preparation and the complete
removal of all polyps. If any of these criteria are not attained, future
exam intervals must be reduced [5].
The need to detect colorectal adenomas and cancer has led to the
implementation of new methods and technology and in upon current
colonoscopy technology.
Stool DNA testing (Fecal DNA testing - COLOGUARD) is
a stool-based test intended for the qualitative detection of colorectal
neoplasia associated with DNA markers and with the presence of occult
hemoglobin in human stool samples. This method is available and approved
by the US FDA in 2014 [6].
Check cap is a capsule device that produces images of
the colon using low dose radiation and creates a 3-dimensional
reconstructed image of the colon surface. Capsule is swallowed by the
patient and no bowel preparation is needed. This method is under
investigation [7].
Colon capsule endoscopy (CCE) is awireless, minimally
invasive technique for the imaging of the large bowel. It also may be
preferable for high risk patients or who have had problems such as
incomplete exams in the past. Their disadvantages are: high costs, the
need for bowel cleansing and inability to take biopsies. [8].Current indications target patients on whom conventional colonoscopy cannot be or has been incompletely performed [29].
Other potential applications, such as CCR screening and surveillance of
inflammatory bowel disease still require further clarification [8].
Technological advances in colonoscopy intend to
improve visualization of the proximal aspects of colonic folds, anatomic
flexures in order to avoid missed lesions. In this way, Third Eye®
technology (Retroscope and Panoramic) is an auxillary, through-
the-scope device able to retroflex 180° and is intended to visualize
proximal folds and at the anatomical flexures of the colon. A video
camera and a light-emitting diode (LED) illumination is located in the
tip of the device, providing continuous retrograde image during the
procedure [9].
Other devices provides a high resolution, with higher
field of view such as Fuse® Full Spectrum Endoscopy® colonoscopy
platform and Extra-Wide-Angle-View colonoscope [10].
The NaviAid™ G-EYE™ Systemis is a colonoscope with a balloon, which can
be inflated, attached to the flexible tip of a standard colonoscope [11].
The mechanical flattening and straightening of haustral folds with the
inflated balloon allows one to view hidden anatomical areas, thus
increasing adenoma detection. Reported that the NaviAid™ G-EYE™ balloon
colonoscopy detected 81% more adenomas (P < 0.001) than did the
standard colonoscope. Procedure time and the incidence of complete
colonoscopy with cecal intubation did not differ between groups. No
adverse events were reported [11,12].
To Know More About Advanced Research in Gastroenterology &
Hepatology Journal
click on:
https://juniperpublishers.com/argh/index.php
https://juniperpublishers.com/argh/index.php
Comments
Post a Comment